The epithelial barrier theory and its associated diseases

The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial barrier theory came to light explaining the growing prevalence and exacerbations of these diseases worldwide. It attributes their onset to a functionally impaired epithelial barrier triggered by the toxicity of the exposed substances, associated with microbial dysbiosis, immune system activation, and inflammation. Diseases encompassed by the epithelial barrier theory share common features such as an increased prevalence after the 1960s or 2000s that cannot (solely) be…

• NS
  National Science Foundation
• A
  Amgen
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• FA
  Food Allergy Research and Education
• NP
  Novartis Pharmaceuticals Corporation
• RP
  Regeneron Pharmaceuticals
• IT
  Immune Tolerance Network
• AT
  Allergy Therapeutics
• I
  Incyte
• NI
  National Institute for Health and Care Research
• AA
  Asthma and Lung UK
• EC
  European Commission
• RT
  Rosetrees Trust
• SN
  Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
• PS
  Promedica Stiftung
• EA
  European Academy of Allergy and Clinical Immunology
• LF
  LEO Fondet
• LP
  LEO Pharma
• NI
  National Institutes of Health
• MR
  Medical Research Council

  Awards: MR/M008517/1, MR/T032081/1
• BA
  Biotechnology and Biological Sciences Research Council
• NI
  National Institute of Allergy and Infectious Diseases